Oncolytics Biotech Inc.
ONCYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Oncolytics Biotech Inc. (ONCY) is listed under Biotechnology. The company carries a $107.5M market cap, placing it firmly in the micro-cap category. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Market Cap
$107.5M
Beta
1.15
P/E (TTM)
—
P/E (Fwd)
-3.47
EPS (TTM)
$-0.35
EPS (Fwd)
$-0.24
ROE
—
ROA
-211.2%
Cash
$4.1M
Total Debt
$448,000
Free CF
-$12.0M
52W Change
-34.4%
Annual Financials
Cash vs Debt
Where ONCY stands vs its 150-day and 200-day moving averages
As of the August 20, 2026 close, ONCY finished 10.75% below its 150-day moving average ($0.93) and 12.63% below its 200-day moving average ($0.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ONCY overbought or oversold?
At the August 20, 2026 close, ONCY's RSI(14) was 72.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $4.1M in cash and $448K in debt, ONCY maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$12.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Oncolytics Biotech Inc.'s trajectory.